

## H0604 Lot No. 1010191

Human Liver Microsomes

Mixed Gender, CMV-, Pool of 15

0.5 mL at 20 mg protein / mL

Suspension medium: 250 mM sucrose

Specific Content and Enzyme Activities			Content / Rate
Cytochrome P450 content	(nmol/mg protein)		0.495
Cytochrome b <sub>5</sub> content	(nmol/mg protein)		0.419
NADPH-cytochrome c reductase	(nmol/mg protein/min)		170 ± 26
Enzyme	Marker Substrate Reaction	[S] (μM)	Rate (pmol/mg protein/min)
CYP1A2	Phenacetin O-dealkylation	80	426 ± 83
CYP2A6	Coumarin 7-hydroxylation	50	1140 ± 40
CYP2B6	Bupropion hydroxylation	500	911 ± 52
CYP2C8	Amodiaquine N-dealkylation	20	3110 ± 140
CYP2C9	Diclofenac 4'-hydroxylation	100	3180 ± 60
CYP2C19	S-Mephenytoin 4'-hydroxylation	400	75.4 ± 4.5
CYP2D6	Dextromethorphan O-demethylation	80	320 ± 7
CYP2E1	Chlorzoxazone 6-hydroxylation	500	1260 ± 50
CYP3A4/5	Testosterone 6β-hydroxylation	250	3820 ± 460
CYP3A4/5	Midazolam 1'-hydroxylation	30	860 ± 17
CYP4A11	Lauric acid 12-hydroxylation	100	1260
FMO	Benzydamine N-oxygenation	500	1090 ± 10
UGT1A1	17β-Estradiol 3-glucuronidation	100	5950 ± 270
UGT1A4	Trifluoperazine glucuronidation	25	790 ± 67
UGT1A6	1-Naphthol glucuronidation	500	19200 ± 300
UGT1A9	Propofol glucuronidation	50	6780 ± 440
UGT2B7	Morphine 3-glucuronidation	1000	3210 ± 230

Characterization is performed when the first lot of a product from a given subcellular fraction (e.g., S9) is prepared. Subsequent lots are subject to a verification test only. Values for enzyme activities were determined at a single substrate concentration and are mean ± standard deviation of three or more determinations.

To measure cytochrome P450 (CYP) activity, liver microsomes (50 μg/mL) were incubated in triplicate at 37 ± 1°C for 10 minutes in potassium phosphate buffer (50 mM, pH 7.4), containing MgCl<sub>2</sub> (3.0 mM), EDTA (1.0 mM), NADP (1.0 mM), glucose-6-phosphate (5.0 mM), glucose-6-phosphate dehydrogenase (1 Unit/mL) and marker substrate, at the final concentrations indicated. Metabolite formation was determined by validated LC-MS/MS methods with deuterated metabolites as internal standards. FMO activity was measured under similar conditions except the protein concentration was 1 mg/mL and the buffer was 49 mM Tricine (pH 8.5)

To measure UDP-glucuronosyltransferase (UGT) activity, liver microsomes (10 - 250 μg/mL) were incubated in triplicate at 37 ± 1°C for 5 or 10 minutes in Tris-HCl (100 mM, pH 7.7 at 37°C), CHAPS (0.5 mM), EDTA (1.0 mM), MgCl<sub>2</sub> (10 mM), D-saccharic acid 1,4-lactone (100 μM), uridine diphosphate-glucuronic acid (8.0 mM) and marker substrate at the final concentrations indicated.



### Store at -80°C

CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for *in vitro* use only.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.

Datasheet prepared 06 November 2012

## Donor Information

Sample	Gender	Age (Yrs)	Race	Cause of Death
229	M	62	Caucasian	Cerebrovascular accident
231	F	61	Caucasian	Cerebrovascular accident
259	M	57	Caucasian	Anoxia
321	M	58	Caucasian	Cerebrovascular accident
348	F	59	Caucasian	Anoxia
370	M	45	Caucasian	Anoxia
382	F	19	Caucasian	Head trauma
383	F	52	Caucasian	Cerebrovascular accident
426	F	51	Caucasian	Cerebrovascular accident
442	M	49	Caucasian	Head trauma
447	F	54	Caucasian	Anoxia
452	M	29	Caucasian	Head trauma
457	M	43	African American	Anoxia
489	M	46	Caucasian	Cerebrovascular accident
509	M	32	Caucasian	Head trauma

### **Serology information**

- All donors tested negative for cytomegalovirus
- RPR\*: 14 donors tested negative and 1 donor was not determined
- HIV, HTLV, HbsAg, and HCV\*\*: All donors tested negative.

\* Rapid Plasma Reagin

\*\* Antibody to Human Immunodeficiency Virus, Antibody to Human T Cell Lymphotropic Virus, Hepatitis B Surface Antigen, Antibody to Hepatitis C Virus, respectively.

These data were generated by and are the property of XenoTech. These data are not to be reproduced, published or distributed without the express written consent of XenoTech.